Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of SYP-1512 and Revlimid in Healthy Males
NCT03208218Phase 1Completed
- Sponsor
- Samyang Biopharmaceuticals Corporation
- Start
- Aug 2016
- Primary completion
- Aug 2016
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of lenalidomide in multiple myeloma (MM) (2 arms), sponsored by Samyang Biopharmaceuticals Corporation. Primary endpoints: Area Under the Curve to the last measurable concentration and Maximum Plasma Concentration. Started Aug 2016; status: completed.
02
Drugs
lenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03208218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03208218.